Institut de Biologie de l'Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, Université PSL, CNRS, INSERM, Paris, France.
J Physiol. 2022 Jan;600(2):233-259. doi: 10.1113/JP280875. Epub 2021 Aug 17.
NMDA receptors (NMDARs) are glutamate-gated ion channels that play key roles in synaptic transmission and plasticity. Both hyper- and hypo-activation of NMDARs are deleterious to neuronal function. In particular, NMDAR hypofunction is involved in a wide range of neurological and psychiatric conditions like schizophrenia, intellectual disability, age-dependent cognitive decline, or Alzheimer's disease. While early medicinal chemistry efforts were mostly focused on the development of NMDAR antagonists, the last 10 years have seen a boom in the development of NMDAR positive allosteric modulators (PAMs). Here we review the currently developed NMDAR PAMs, their pharmacological profiles and mechanisms of action, as well as their physiological effects in healthy animals and animal models of NMDAR hypofunction. In light of the complexity of physiological outcomes of NMDAR PAMs in vivo, we discuss the remaining challenges and questions that need to be addressed to better grasp and predict the therapeutic potential of NMDAR positive allosteric modulation.
N-甲基-D-天冬氨酸受体(NMDARs)是谷氨酸门控离子通道,在突触传递和可塑性中发挥关键作用。NMDAR 的过度和不足激活对神经元功能都是有害的。特别是,NMDAR 功能不足与广泛的神经和精神疾病有关,如精神分裂症、智力障碍、与年龄相关的认知能力下降或阿尔茨海默病。虽然早期的药物化学研究主要集中在开发 NMDAR 拮抗剂上,但在过去 10 年中,NMDAR 正变构调节剂(PAMs)的开发取得了蓬勃发展。在这里,我们综述了目前开发的 NMDAR PAMs 及其药理学特性和作用机制,以及它们在健康动物和 NMDAR 功能不足动物模型中的生理效应。鉴于 NMDAR PAMs 在体内的生理结果的复杂性,我们讨论了仍需解决的挑战和问题,以更好地掌握和预测 NMDAR 正变构调节的治疗潜力。